Compare ADMA Biologics Inc (ADMA) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Clear Secure Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Clear Secure Inc trades at $55.46 (market cap $5.63B). The key difference: Clear Secure Inc is far larger — about 2.6× ADMA Biologics Inc's market cap, and Clear Secure Inc pays a 1.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | YOU | |
|---|---|---|
Market Cap | $2.13B | $5.63B |
Sector | Health | Technology |
52-Week High | $20.38 | $62.36 |
52-Week Low | $7.60 | $28.38 |
Enterprise Value | $2.20B | $4.94B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Clear Secure (YOU) trades at $56.74, up 5.48% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated at P/E 45.39. Recent Q1 2026 earnings beat expectations, and the AWS partnership expansion signals growth potential. Analyst sentiment is mixed with 44% buy ratings and consensus target near current price.
Outlook remains positive given strong member growth and cash flow generation, but high valuation multiples and competitive pressures present risks. The stock's technical overbought condition near resistance at $58 suggests potential near-term consolidation before further upside. Institutional interest appears balanced with moderate net cash flow growth supporting expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
